Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

BACKGROUND: Early clinical data from studies of the NVX-CoV2373 vaccine (Novavax), a recombinant nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that contains the full-length spike glycoprotein of the prototype strain plus Matrix-M adjuvant, showed that the...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:N Engl J Med
Autores principales: Heath, Paul T., Galiza, Eva P., Baxter, David N., Boffito, Marta, Browne, Duncan, Burns, Fiona, Chadwick, David R., Clark, Rebecca, Cosgrove, Catherine, Galloway, James, Goodman, Anna L., Heer, Amardeep, Higham, Andrew, Iyengar, Shalini, Jamal, Arham, Jeanes, Christopher, Kalra, Philip A., Kyriakidou, Christina, McAuley, Daniel F., Meyrick, Agnieszka, Minassian, Angela M., Minton, Jane, Moore, Patrick, Munsoor, Imrozia, Nicholls, Helen, Osanlou, Orod, Packham, Jonathan, Pretswell, Carol H., San Francisco Ramos, Alberto, Saralaya, Dinesh, Sheridan, Ray P., Smith, Richard, Soiza, Roy L., Swift, Pauline A., Thomson, Emma C., Turner, Jeremy, Viljoen, Marianne E., Albert, Gary, Cho, Iksung, Dubovsky, Filip, Glenn, Greg, Rivers, Joy, Robertson, Andreana, Smith, Kathy, Toback, Seth
Formato: Artigo
Lenguaje:Inglês
Publicado: Massachusetts Medical Society 2021
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8262625/
https://ncbi.nlm.nih.gov/pubmed/34192426
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa2107659
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares